{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:21:06Z","timestamp":1794626466015,"version":"4.9.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Background<\/jats:title>\n                  <jats:p>\n                    Metastatic pheochromocytomas and paragangliomas (MPPGLs) are rare tumors with limited treatment options. High-specific-activity\n                    <jats:sup>131<\/jats:sup>\n                    I-MIBG (HSA-\n                    <jats:sup>131<\/jats:sup>\n                    I-MIBG) is the only US Food and Drug Administration\u2013approved therapy for MPPGL. We studied the efficacy and safety of HSA-\n                    <jats:sup>131<\/jats:sup>\n                    I-MIBG in routine clinical practice.\n                  <\/jats:p>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>The primary endpoints were objective response rate (ORR) and disease control rate (DCR). Secondary endpoints were duration of response, blood pressure control, safety, overall and progression-free survival rates, MIBG uptake, and correlations with genetic background.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 25 patients. Twenty-four patients had distant metastases, 17 (68%) had hormonally active tumors, and 13 (52%) had previously received antineoplastic treatment. In 24 evaluable patients, the ORR was 38%, including 2 patients with complete response, and the DCR was 83%; median time to response was 12.5 months (95% confidence interval, 4.6\u201325.1). Twelve patients had sporadic disease, among whom the ORR was 25% and DCR was 83%. Twelve patients had hereditary disease (\n                      <jats:italic toggle=\"yes\">SDHB<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">VHL<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">RET<\/jats:italic>\n                      ); among these, the ORR was 50%, and DCR was 83%. Plasma metanephrines normalized in 30% of patients and improved by greater than 50% in 46%. Sixteen patients had hormonally active tumors and hypertension; in 9 (56%) of these, blood pressure normalized, leading to discontinuation of antihypertensive therapy.\n                    <\/jats:p>\n                    <jats:p>The most common adverse events were grades 1\u20132 nausea\/vomiting and transient bone marrow suppression. One patient developed premature ovarian failure. Reversible grades 3\u20134 myelosuppression were seen in 7 patients (28%). One patient had fatal pneumonitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      HSA-\n                      <jats:sup>131<\/jats:sup>\n                      I-MIBG is associated with a high DCR in patients with MPPGL, regardless of underlying genetic mutation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005184","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T17:00:05Z","timestamp":1713373205000},"page":"610-620","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["High-Specific-Activity 131I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma"],"prefix":"10.1097","volume":"49","author":[{"given":"Ruaa","family":"Al-Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania Balderrama","family":"Brondani","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Sawani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl L.","family":"Potter","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Waguespack","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeena","family":"Varghese","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouhammed Amir","family":"Habra","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","year":"2017","journal-title":"J Clin Endocrinol Metabol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s00268-022-06862-w","article-title":"Genotype-phenotype correlations and clinical outcomes in 155 cases of pheochromocytoma and paraganglioma","volume":"47","year":"2023","journal-title":"World J Surg"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/clinem\/dgac677","article-title":"TNM staging and overall survival in patients with pheochromocytoma and sympathetic paraganglioma","volume":"108","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2012-4231","article-title":"Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma","volume":"98","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","year":"2021","journal-title":"Pancreas"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"bvab163","DOI":"10.1210\/jendso\/bvab163","article-title":"Dopamine-secreting pheochromocytoma and paraganglioma","volume":"5","year":"2021","journal-title":"J Endocr Soc"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","article-title":"Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma","volume":"15","year":"2013","journal-title":"Curr Oncol Rep"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11912-022-01197-0","article-title":"New directions in treatment of metastatic or advanced pheochromocytomas and sympathetic paragangliomas: an American, contemporary, contemporary, pragmatic approach","volume":"24","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13139-015-0331-7","article-title":"Diagnostic performance of (68)Ga-DOTATATE PET\/CT, (18)F-FDG PET\/CT and (131)I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma","volume":"49","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"key":"bib11-20250621","first-page":"107","article-title":"131-I-meta-iodobenzylguanidine in treatment of malignant phaeochromocytomas","volume":"2","year":"1983","journal-title":"Lancet"},{"key":"bib12-20250621","first-page":"209","article-title":"Treatment of malignant pheochromocytoma with a new radiopharmaceutical","volume":"96","year":"1983","journal-title":"Trans Assoc Am Physicians"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/cancers11071018","article-title":"Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine","volume":"11","year":"2019","journal-title":"Cancers (Basel)"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/jc.2017-02030","article-title":"Phase 1 study of high-specific-activity I-131 MIBG for metastatic and\/or recurrent pheochromocytoma or paraganglioma","volume":"103","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","year":"2009","journal-title":"Eur J Cancer"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/RLU.0000000000004598","article-title":"Proposed MIBG scan-based tumor response criteria of high-specific-activity 131I-MIBG therapy in metastatic pheochromocytoma\/paraganglioma","volume":"48","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"Suppl 1(Suppl 1)","key":"bib18-20250621","first-page":"122S","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","year":"2009","journal-title":"J Nucl Med"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET Response Criteria in Solid Tumors 1.0","volume":"280","year":"2016","journal-title":"Radiology"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40644-016-0084-2","article-title":"(68)Ga-DOTATATE and (18)F-FDG PET\/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity","volume":"16","year":"2016","journal-title":"Cancer Imaging"},{"key":"bib21-20250621","first-page":"e220236","article-title":"Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma\/paraganglioma","volume":"30","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","year":"2018","journal-title":"Ann Surg"},{"key":"bib23-20250621","first-page":"83","article-title":"False-negative (1)(2)(3)I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease","volume":"19","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"127","DOI":"10.14310\/horm.2002.11121","article-title":"Familial paraganglioma: a novel presentation of a case and response to therapy with radiolabelled MIBG","volume":"3","year":"2004","journal-title":"Hormones (Athens)"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-20-3703","article-title":"High-specific-activity-(131)I-MIBG versus (177)Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma","volume":"27","year":"2021","journal-title":"Clin Cancer Res"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/0194599815627667","article-title":"Head and neck paragangliomas: an update on evaluation and management","volume":"154","year":"2016","journal-title":"Otolaryngol Head Neck Surg"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/RLU.0000000000004519","article-title":"Functional imaging evidence of tumor response to high-specific-activity 131I-MIBG therapy in an 84-year-old patient with metastatic pheochromocytoma\/paraganglioma","volume":"48","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/CCO.0b013e32834bcc2a","article-title":"Therapy-related myeloid neoplasms","volume":"23","year":"2011","journal-title":"Curr Opin Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T15:01:26Z","timestamp":1750518086000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005184","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,17]]}}}